Filter by content type
Filter by year
Mon, 04/01/2019 - 13:00 - … ASCO Annual Meeting: Vaccinex, Inc. - Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in … ASCO Annual Meeting: Vaccinex, Inc. - Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) …
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
November 10, 2022 - … . Vaccinex reported that results of this Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate (ORR) for … . Vaccinex reported that results of this Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate …
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis
January 4, 2022 - … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate (ORR) for … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate …
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
September 27, 2023 - … rationale builds on safety and efficacy data from the CLASSICAL-Lung study of pepinemab and avelumab and the observation that … rationale builds on safety and efficacy data from the CLASSICAL-Lung study of pepinemab and avelumab and the …
Vaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer
October 6, 2016 - … Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer … Vaccinex Announces Clinical Collaboration with … Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Vaccinex Announces Clinical Collaboration with … Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer 10/06/16 General Rochester, New York, October 6, …
… Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in … Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) …
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 - … The trial rationale builds on safety and efficacy of the CLASSICAL-Lung study of pepinemab and avelumab in lung cancer and the … The trial rationale builds on safety and efficacy of the CLASSICAL-Lung study of pepinemab and avelumab in lung cancer …
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update
May 16, 2022 - … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies, partially offset by setup expenses … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies, partially offset by setup …
ASCO Annual Meeting Poster: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
ASCO Annual Meeting Abstract: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Pagination
- Previous page
- Page 4
- Next page